Stifel reiterated a Buy rating on Denali Therapeutics (DNLI), saying he continues to like the shares here even as the company announced that its recent ALS program failed in the HEALSEY ALS platform trial. This was a very high-risk/high-reward option, but Wall Street expectations here were fairly low and the stock had been under pressure during the session possibly due to the concurrent failure of another AbbVie (ABBV) program, the analyst tells investors in a research note. The firm noted that eIF2b is not core to its thesis, and that it likes Denali on weakness.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics announces HEALEY ALS trial regimen misses endpoints
- Denali falls 9% to $18 afteramyotrophic lateral sclerosis study miss
- Denali Therapeutics initiated with an Outperform at Baird
- Block upgraded, Bumble downgraded: Wall Street’s top analyst calls
- Denali Therapeutics initiated with an Outperform at William Blair